1. Bito L et al (2001) From the bench to the clinical practice. Proctor Lecture Award. Reproduced in IOVS
2. Fechtner RD, Airaksinen PJ, Getson AJ, Lines CR, Adamsons IA (2004) COSOPT versus XALATAN Study Groups. Efficacy and tolerability of the dorzolamide 2 %/timolol 0.5 % combination (COSOPT) versus 0.005 % (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 82:42–48
3. Konstas AG et al (2003) Twenty four hour diurnal curve comparison of commercially available latanoprost 0.005 % versus the timolol and dorzolamide fixed combination. Ophthalmology 110:1357–1360
4. Coleman AL, Lerner F, Bernstein P, Whitcup SM (2005) A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Jules Stein Eye Institute, UCLA, Los Angeles, California 90095, USA. Ophthalmology 112(2):357–358
5. Sampaolesi R, Calixto N, Carvalho CA, Reca R (1968) Diurnal variation of intraocular pressure in healthy, suspected and glaucomatous eyes. Mod Probl Ophthalmol 6:1–23 (Karger 1968)